Cargando…
Blood-based molecular biomarkers for Alzheimer’s disease
A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer’s disease (AD) and to identifying patients for receiving future disease-modifying treatments is the limited capacity of the current health system to find and diagnose patients with early AD pathology...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437931/ https://www.ncbi.nlm.nih.gov/pubmed/30922367 http://dx.doi.org/10.1186/s13041-019-0448-1 |